Surface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions
Molecular Pharmaceutics · 04.08.2025 · 22 (8) · 4587-4596
DOI: 10.1021/acs.molpharmaceut.5c00068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 07.07.2025. Verfasst von Benjamin Lew und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pre-Pivotal Drug Product Technologies, Process Development, Operations, Amgen, Thousand Oaks, California 91320, United States. Hauptthemen laut MEDLINE: Surface Plasmon Resonance, Nanoparticles, Apolipoproteins E, Lipids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) are an essential delivery platform for nucleic acid payloads that are susceptible to degradation or elimination. Upon administration, a biomolecular corona composed of serum proteins forms around the LNP surface, which is crucial for tissue targeting and biodistribution. One essential protein that drives the distribution of LNPs is apolipoprotein E (ApoE). In this work, we used ApoE as a model protein to probe LNP-protein interactions utilizing a surface plasmon resonance (SPR) interaction assay comparable to the conventional quartz crystal microbalance with dissipation (QCM-D) assay. We employed two LNP formulations with or without payload and various ApoE homologs to establish the SPR method as an in vitro tool to screen LNP formulations and explore species cross-reactivity in LNP-protein interactions. Two binding models were applied to capture the difference in binding behaviors of different ApoE homologs in terms of relative binding response and association kinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pre-Pivotal Drug Product Technologies, Process Development, Operations, Amgen, Thousand Oaks, California 91320, United States.
- Amgen Postdoctoral Fellow Program, Amgen, Thousand Oaks, California 91320, United States.
- Lead Discovery and Characterization, Research, Amgen, Thousand Oaks, California 91320, United States.
- Complex Biologics, Amgen Research, Amgen, Thousand Oaks, California 91320, United States.
ORCID-Profile: Benjamin Lew, Jacob A Lewis, Angela C Wagoner, Steve Halaby, Justin K Murray, Brendan R Amer
Förderung
- Amgen
Zitieren
APA
Lew, B., Chhabra, S., Lewis, J. A., Wagoner, A. C., Hsu, A., Halaby, S., Sharma, P., Murray, J. K., Kinderman, F., Piedmonte, D. M., & Amer, B. R. (2025). Surface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions. Molecular Pharmaceutics, 22(8), 4587-4596. https://doi.org/10.1021/acs.molpharmaceut.5c00068
Vancouver
Lew B, Chhabra S, Lewis JA, Wagoner AC, Hsu A, Halaby S, et al. Surface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions. Molecular Pharmaceutics. 2025;22(8):4587-4596. doi:10.1021/acs.molpharmaceut.5c00068
BibTeX
@article{Lew2025,
author = {Lew, Benjamin and Chhabra, Sandeep and Lewis, Jacob A and Wagoner, Angela C and Hsu, Angel and Halaby, Steve and Sharma, Pooja and Murray, Justin K and Kinderman, Francis and Piedmonte, Deirdre Murphy and Amer, Brendan R},
title = {Surface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {8},
pages = {4587--4596},
doi = {10.1021/acs.molpharmaceut.5c00068}
}
EUVIMED